September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Retinal imaging in early and late Alzheimer’s disease
Author Affiliations & Notes
  • Lajos Csincsik
    ORBIT, UCL Institute of Ophthalmology, London, United Kingdom
  • Timothy Shakespeare
    Dementia Research Centre, UCL Institute of Neurology, London, United Kingdom
  • Nicola Quinn
    Queen's University - Centre for Experimental Medicine, Belfast, United Kingdom
  • Ruth E Hogg
    Queen's University - Centre for Experimental Medicine, Belfast, United Kingdom
  • Sebastian Crutch
    Dementia Research Centre, UCL Institute of Neurology, London, United Kingdom
  • Ritchie Craigh
    University of Edinburgh, Edinburgh, United Kingdom
  • Tunde Peto
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    ORBIT, UCL Institute of Ophthalmology, London, United Kingdom
  • Imre Lengyel
    ORBIT, UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships   Lajos Csincsik, None; Timothy Shakespeare , None; Nicola Quinn, None; Ruth Hogg, None; Sebastian Crutch, None; Ritchie Craigh , None; Tunde Peto, None; Imre Lengyel, None
  • Footnotes
    Support  OPTOS plc
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3373. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lajos Csincsik, Timothy Shakespeare, Nicola Quinn, Ruth E Hogg, Sebastian Crutch, Ritchie Craigh, Tunde Peto, Imre Lengyel; Retinal imaging in early and late Alzheimer’s disease. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3373.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : It has been suggested that the development of Alzheimer’s disease (AD) is associated with thinning of the peripapillary retinal nerve fiber layer (ppRNFL) due to ganglion cell loss and accumulation of drusen and that these reflect atrophy and plaque deposition in the brain, respectively. Here we report the results of baseline and progression characteristics of two prospective small studies that examined changes on ultra-widefield imaging (UWFI) and spectral-domain optical coherence tomography (OCT) to gain insights into retinal changes associated with AD.

Methods : Color and autofluorescence UWFI and OCT images were acquired by Optos 200TX and Optos OCT SLO, respectively. In study 1 (S1), UWFI images of 72 healthy controls (HC) and 46 AD patients (Mini Mental Score Examination (MMSE) <20) were analysed for presence/absence and progression of drusen at baseline and at 2-year follow-up. In study 2 (S2), ppRNFL and peripapillary whole retinal (ppWR) thickness as well as macular volume (MV) and thickness (MT) were analysed at baseline and at 1-year follow-up (FU) on OCT images of 72 [4 FU] HC (MMSE>28), 23 [3 FU] typical AD (tAD) (MMSE<20) and 26 [5 FU] posterior cortical atrophy (PCA; MMSE<22) patients. The studies had full Ethical Committee approval. Statistical analysis was carried out using STATA and SPSS.

Results : In S1, using UWFI we found that there is a significantly higher prevalence of hard drusen in the peipheral retina only in AD patients at baseline (p<0.05). Drusen numbers increased significantly in AD patients by the 2-year follow-up (p<0.05). In S2, using OCT, disease duration at baseline was not associated with any of the examined parameters (p>0.05 for all groups). However, the ppRNFL thickness measurements showed a significant age related decline (p<0.006). Importantly, UWFI and OCT imaging of the retina was quick and well tolerated in both studies. There were some difficulties with maintaining fixation or generating good quality images of patients with more advanced disease.

Conclusions : These studies suggest that peripheral retinal hard drusen deposition is associated with AD, suggesting that UWFI might become a useful tool in monitoring progression in AD. The clinical utility of OCT on individual patient’s progression is yet to be determined.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×